LUMOS PHARMA INC. - COMMON STOCK

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

10 مارس 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Participate in Upcoming Investor Conferences

10 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

23 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

05 يناير 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Participate in Upcoming Investor Conferences

10 نوفمبر 2021 16:06:38 بحسب Nasdaq GlobeNewswire

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

03 نوفمبر 2021 15:01:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

21 أكتوبر 2021 15:05:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Participate in September Investor Conferences

02 سبتمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

05 أغسطس 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer

03 أغسطس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

02 أغسطس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board

26 يوليو 2021 15:18:40 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

22 يوليو 2021 07:00:04 بحسب Nasdaq GlobeNewswire

Lumos Pharma Announces Clinical Updates

20 يوليو 2021 15:01:00 بحسب Nasdaq GlobeNewswire

Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment

28 يونيو 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference

19 مايو 2021 08:00:02 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit

13 مايو 2021 08:00:01 بحسب Nasdaq GlobeNewswire

Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

05 مايو 2021 15:01:00 بحسب Nasdaq GlobeNewswire

Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021

28 أبريل 2021 08:00:00 بحسب Nasdaq GlobeNewswire

Newly Released Data on Three PGHD Patients Treated with LUM-201 in Prior Phase 2 Study To Be Presented in Lumos Pharma Key Opinion Leader Webinar

27 أبريل 2021 07:00:01 بحسب Nasdaq GlobeNewswire